Aries Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Aries Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Hold	605	–	–	0.06%	200
2026 Q1	$270K	Hold	605	–	–	0.06%	197
2025 Q4	$274K	Hold	605	–	–	0.06%	193
2025 Q3	$237K	Hold	605	–	–	0.06%	207
2025 Q2	$269K	Hold	605	–	–	0.07%	193
2025 Q1	$293K	Buy	+605	New	+$282K	0.08%	183
2024 Q4	–	Sell	-475	Closed	-$221K	–	235
2024 Q3	$221K	Hold	475	–	–	0.06%	211
2024 Q2	$223K	Buy	+475	New	+$206K	0.07%	189

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Aries Wealth Management's VRTX Position: Q2 2026 in Review

Aries Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 605 shares worth $301K. The position accounts for 0.06% of the portfolio, ranked #200.

Aries Wealth Management first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Aries Wealth Management held 605 shares of Vertex Pharmaceuticals worth $301K as of Q2 2026.
Aries Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.06% of Aries Wealth Management's portfolio in Q2 2026, its #200 holding.
Aries Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Aries Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.